Oslo, Norway – May 24, 2018 – At the 13th Congress of The International Society For The Study Of Fatty Acids And Lipids (ISSFAL) in Las Vegas, USA, from May 27-31, four new omega-3 clinical abstracts from BASF will be presented, which investigate the role and importance of a new omega-3 technology designed to deliver optimal benefits in supplements to consumers. Topics covered will be far ranging and further demonstrate the commercial potential for Accelon™; from impact on cerebral blood flow, to nighttime dosing effect on EPA & DHA levels.
Accelon, with superior omega-3 absorption, was recently launched by BASF. The science behind Accelon is a breakthrough omega-3 absorption technology; the world’s first clinically proven technology to increase absorption of EPA and DHA at a cellular level.
“Our thought process is moving from omega-3 intake to uptake; that is, the correct absorption into the blood stream of EPA and DHA fatty acids that the body requires. If an omega-3 supplement is not fully absorbed, as we now know is invariably the case, then we cannot assume every gram is getting to where it is needed. These new studies show that omega-3 absorption is arguably today’s biggest priority for scientific focus, which represents a significant change of direction for the industry,” explains Per-Olof Larsson, Scientific Affairs Omega-3 Nutrition.
The four BASF clinical studies that will be presented at ISSFAL 2018 can be shared upon request following the congress.
New consumer benefits and category opportunities
“These latest scientific studies are so important because they show that omega-3 enhanced with Accelon absorption technology provides optimized omega-3 benefits for consumers. Our view is that leveraging this science into compelling brand propositions provides brand owners with huge growth opportunities based on new and relevant reasons to believe. We look forward to discussing with the scientific community, key opinion leaders and brand partners how Accelon can help increase penetration and benefit the industry long term,” says Øyvind Ihle, Head of Omega-3 Nutrition. “We’re excited that BASF will once again take a lead role at ISSFAL and be the sponsor of the New Investigator Awards recognizing future research opportunities. We’re really looking forward to meeting potential candidates and partners who share our passion for omega-3 science,” he added.
At the five-day congress, BASF will also sponsor the New Investigator Awards, which recognize and encourage the highest standards of omega-3 research. Designed to encourage investigators at the start of their careers, application for the Awards is made as part of the abstract submission system. Approximately 50 awards of complimentary registration are given, from which the best 10 applicants are selected to receive a cash award.
About the BASF Nutrition & Health division
BASF Nutrition & Health provides a comprehensive product and service portfolio for the human and animal nutrition, pharmaceutical and flavor & fragrance industries. With innovative solutions and modern technologies, we help our customers improve their business efficiency and the sustainability of their products. Our human nutrition solutions include vitamins and carotenoids, plant sterols, emulsifiers and omega-3 fatty acids. Vitamins and carotenoids also form an important part of our animal nutrition portfolio, as do other feed additives such as trace elements, enzymes and organic acids. We provide the pharmaceutical industry with a broad range of excipients and selected large-volume active pharmaceutical ingredients such as ibuprofen and omega-3 fatty acids. Furthermore, we offer aroma ingredients such as citral, geraniol and L-menthol. BASF Nutrition & Health operates sites in Europe, North America, South America and in Asia-Pacific. For more information, go to www.basf.com.
At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. The more than 115,000 employees in the BASF Group work on contributing to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into five segments: Chemicals, Performance Products, Functional Materials & Solutions, Agricultural Solutions and Oil & Gas. BASF generated sales of €64.5 billion in 2017. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (BAS). Further information at www.basf.com.
 Abstract list:
1.A novel self-micro-emulsifying delivery system enhances enrichment of plasma eicosapentaenoic acid and docosahexaenoic acid after single and repeated dosing
2. A novel self-micro-emulsifying delivery system enhances EPA and DHA enrichment in blood mononuclear cells and red blood cells
3.Efficacy Evaluation of 26 Weeks' Dietary Supplementation with DHA- and EPA-enriched Oils on Cerebral Blood Flow in Healthy Adults
4.BEDTIME SUPPLEMENTATION OF EPA AND DHA ELIMINATES THE NIGHT-TIME DIURNAL NADIRS OF THESE N-3 PUFAS